Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498415 | 0.86 | MAPK8 (0.46) | MAPK8MAPK9PIKFYVEGSK3BCDK4 | |
| SCHEMBL6490443 | 0.81 | CSNK1D (0.48) | MAPK8MAPK9GSK3BCDK4MAPK14 | |
| SCHEMBL6488212 | 0.79 | GSK3B (0.50) | GSK3BCDK4MAPK14 | |
| SCHEMBL6487352 | 0.78 | GSK3B (0.42) | MAPK8MAPK9GSK3BCDK4 | |
| SCHEMBL6484935 | 0.77 | CSNK1D (0.49) | MAPK8MAPK9PIKFYVEGSK3BCDK4 | |
| SCHEMBL14593078 | 0.76 | MAPK14 (0.53) | MAPK8MAPK9PIKFYVEGSK3BCDK4 | |
| SCHEMBL6106431 | 0.76 | GSK3B (0.46) | MAPK8MAPK9GSK3BCDK4MAPK14 | |
| SCHEMBL6484913 | 0.76 | MAPK8 (0.53) | MAPK8MAPK9PIKFYVEGSK3BCDK4 | |
| SCHEMBL5725033 | 0.74 | MAPK8 (0.47) | MAPK8MAPK9CDK4MAPK14 | |
| SCHEMBL6108305 | 0.73 | GSK3B (0.44) | MAPK8MAPK9GSK3BCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK8 1906/4885MAPK9 2403/4885ABCB1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.